THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE
Division on Earth and Life Studies
Board on Life Sciences
Board on Agriculture and Natural Resources
Board on Chemical Sciences and Technology
Committee on Future Biotechnology Products and Opportunities to Enhance
Capabilities of the Biotechnology Regulatory System
*****
Congressional Briefings
Wed, Mar 8, 2017
1301 Longworth House Office Bldg. – 1:30 p.m.
and
Wed, Mar 8, 2017
645 Dirksen Senate Office Bldg. – 5:00 p.m.
and
Wed, Mar 22, 2017
394 Ford House Office Bldg. -- 2:00 p.m.
and
Wed, Mar 22, 2017
423 James Madison Bldg. (LoC) -- 3:30 p.m.
on
Preparing for Future Products of Biotechnology
Between 1973 and 2016, the ways to manipulate DNA to endow new characteristics in an organism (that is, biotechnology) have advanced, enabling the development of products that were not previously possible. What will the likely future products of biotechnology be over the next 5–10 years? What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology?
This new report, from the National Academies of Sciences, Engineering, and Medicine, analyzes the future landscape of biotechnology products and seeks to inform forthcoming policy making. This report identifies potential new risks and frameworks for risk assessment and areas in which the risks or lack of risks relating to the products of biotechnology are well understood.
These briefings were for members of Congress and congressional staff only. The report was publicly released on March 9, 2017 and can be found, in its entirety, on the Web site of the National Academies Press.